AAVantgarde Bio has developed an engineered adeno‑associated virus (AAV) platform that can package and deliver transgenes larger than 5 kb to photoreceptor and retinal pigment epithelium cells, overcoming the size limitation of standard AAV vectors. The system provides high retinal transduction efficiency, sustained expression, and a GMP‑compatible manufacturing process, supporting clinical programs for Stargardt disease (ABCA4) and Usher 1B syndrome (MYO7A).
Funding
$65.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FCFounders
Product
Problem
Inherited retinal disorders caused by large gene mutations lack effective treatments because conventional adeno‑associated virus (AAV) vectors cannot accommodate the full-length therapeutic transgenes, leaving patients with conditions such as Stargardt disease and Usher 1B without disease‑modifying options.
Solution
AAVantgarde Bio has engineered a next‑generation AAV platform that expands vector cargo capacity, enabling stable delivery of full‑length large genes to photoreceptor and retinal pigment epithelium cells. The technology achieves high transduction efficiency and sustained expression while maintaining a favorable safety profile in preclinical models. Leveraging this platform, the company is advancing clinical programs for Stargardt disease (ABCA4) and Usher 1B syndrome (MYO7A), supported by FDA orphan‑drug and fast‑track designations. The approach targets the genetic root cause of these IRDs, aiming to preserve or restore vision in patients who currently have no curative options. Manufacturing processes are designed for scalability and regulatory compliance, facilitating broader application to other large‑gene retinal disorders.
Target Audience
The primary customers are retinal specialists and ophthalmology clinics treating patients with inherited retinal disorders, particularly those diagnosed with Stargardt disease or Usher 1B syndrome, as well as pharmaceutical partners seeking a large‑gene delivery platform for ocular gene therapies.
Features
- Engineered AAV capsids optimized for packaging transgenes > 5 kb, overcoming the size limitation of standard AAV vectors
- High‑efficiency retinal transduction demonstrated in multiple disease‑relevant animal models with quantitative expression data
- Long‑term safety and durability validated through chronic dosing studies, showing stable protein levels without adverse immune responses
- GMP‑compatible production pipeline enabling consistent vector quality and batch‑to‑batch reproducibility
- Integrated regulatory strategy yielding FDA orphan‑drug, fast‑track, and UK CTA approvals for lead programs (AAVB‑039, AAVB‑081)
- Clinical trial infrastructure covering Phase 1/2 studies (LUCE‑1, STELLA, CELESTE) with centralized data capture and remote monitoring capabilities
- Platform extensibility to additional large‑gene IRDs, supported by a modular vector design and scalable preclinical validation workflow